Expression of Matrix Metalloproteinases, Tissue Inhibitors of Metalloproteinases and Vascular Endothelial Growth Factor in Canine Mast Cell Tumours

Journal of Comparative Pathology

Volumn 147, Issue 4, 2012, Pages 419-429

  Giantin, M ^a   Aresu, L ^a   Benali, S ^a   Arico A ^a   Morello, E M ^b   Martano, M ^b   Vascellari, M ^c   Castagnaro, M ^a   Lopparelli, R M ^a   Zancanella, V ^a   Granato, A ^c   Mutinelli, F ^c   Dacasto, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE VENEZIE   (Italy)

Author keywords

Dog; Mast cell tumour; Matrix metalloproteinase; Vascular endothelial growth factor

Indexed keywords

GELATIN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN; VASCULOTROPIN A;

ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CANCER GRADING; DOG; FEMALE; GENE EXPRESSION; MALE; MASTOCYTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETICULOENDOTHELIAL NEOPLASM; ZYMOGRAPHY;

ANIMALS; DNA, NEOPLASM; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; MALE; MAST-CELL SARCOMA; MATRIX METALLOPROTEINASES; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

CANIS FAMILIARIS;

EID: 84868622339     PISSN: 00219975     EISSN: 15323129     Source Type: Journal    
DOI: 10.1016/j.jcpa.2012.01.011     Document Type: Article

References (60)

1. Aresu L., Giantin M., Morello E.M., Vascellari M., Castagnaro M., et al. Matrix metalloproteinases and their inhibitors in canine mammary tumors. BMC Veterinary Research 2011, 7:33.
2. Aupperle H., Thielebein J., Kiefer B., Marz I., Dinges G., et al. Expression of genes encoding matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in normal and diseased canine mitral valves. Journal of Comparative Pathology 2009, 140:271-277.
3. Caenazzo C., Onisto M., Sartor L., Scalerta R., Giraldo A., et al. Augmented membrane type 1 matrix metalloproteinase (MT1-MMP):MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis. Clinical Cancer Research 1998, 4:2179-2186.
4. Davies B., Waxman J., Wasan H., Abel P., Williams G., et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Research 1993, 53:5365-5369.
5. DeClerck Y.A., Yean T.D., Chan D., Shimada H., Langley K.E. Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Research 1991, 51:2151-2157.
6. Elpek G.O., Gelen T., Aksoy N.H., Erdoĝan A., Dertsiz L., et al. The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus. Journal of Clinical Pathology 2001, 54:940-944.
7. Funahashi Y., Shawber C.J., Sharma A., Kanamaru E., Choi Y.K., et al. Notch modulates VEGF action in endothelial cells by inducing matrix metalloprotease activity. Vascular Cell 2011, 3:2.
8. Gentilini F., Calzolari C., Turba M.E., Agnoli C., Fava D., et al. Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs. Leukemia Research 2005, 29:1263-1269.
9. Gil da Costa R.M., Matos E., Rema A., Lopes C., Pires M.A., et al. CD117 immunoexpression in canine mast cell tumours: correlations with pathological variables and proliferation markers. BMC Veterinary Research 2007, 3:19.
10. Gomez D.E., Alonso D.F., Yoshiji H., Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. European Journal of Cell Biology 1997, 74:111-122.
11. Hirayama K., Yokota H., Onai R., Kobayashi T., Kumata T., et al. Detection of matrix metalloproteinases in canine mammary tumours: analysis by immunohistochemistry and zymography. Journal of Comparative Pathology 2002, 127:249-256.
12. Iamaroon A., Pongsiriwet S., Jittidecharaks S., Pattanaporn K., Prapayasatok S., et al. Increase of mast cells and tumor angiogenesis in oral squamous cell carcinoma. Journal of Oral Pathology and Medicine 2003, 32:195-199.
13. Kawai K., Uetsuka K., Doi K., Nakayama H. The activity of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in mammary tumors of dogs and rats. Journal of Veterinary Medical Sciences 2006, 68:105-111.
14. Kim K.J., Li B., Winer J., Armanini M., Gillett N., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
15. Kondo K., Muramatsu M., Okamoto Y., Jin D., Takai S., et al. Expression of chimase-positive cells in gastric cancer and its correlation with the angiogenesis. Journal of Surgical Oncology 2006, 93:36-42.
16. Kut C., MacGabhann F., Popel A.S. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. British Journal of Cancer 2007, 97:978-985.
17. Ladomery M.R., Harper S.J., Bates D.O. Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. Cancer Letters 2007, 249:133-142.
18. Lambert E., Dasse E., Haye B., Petitfrere E. TIMPs as multifacial proteins. Critical Reviews in Oncology Hematology 2004, 49:187-198.
19. Leibman N.F., Lana S.E., Hansen R.A., Powers B.E., Fettman M.J., et al. Identification of matrix metalloproteinases in canine cutaneous mast cell tumors. Journal of Veterinary Internal Medicine 2000, 14:583-586.
20. Liotta L.A., Stetler-Stevenson W.G., Steeg P.S. Cancer invasion and metastasis: positive and negative regulatory elements. Cancer Investigations 1991, 9:543-551.
21. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(Delta Delta C[T]) method. Methods 2001, 25:402-408.
22. Loukopoulos P., Mungall B.A., Straw R.C., Thornton J.R., Robinson W.F. Matrix metalloproteinase-2 and -9 involvement in canine tumors. Veterinary Pathology 2003, 40:382-394.
23. MacDougall J.R., Matrisian L.M. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Reviews 1995, 14:351-362.
24. Maiolino P., De Vico G., Restucci B. Expression of vascular endothelial growth factor in basal cell tumours and in squamous cell carcinomas of canine skin. Journal of Comparative Pathology 2000, 123:141-145.
25. Matiasek L.A., Platt S.R., Adams V., Scase T.J., Keys D., et al. Ki-67 and vascular endothelial growth factor expression in intracranial meningiomas in dogs. Journal of Veterinary Internal Medicine 2009, 23:146-151.
26. Mederle O., Mederle N., Bocan E.V., Ceauşu R., Raica M. VEGF expression in dog mastocytoma. Revista Medico-Chirurgicala a Societatii de Medici si Naturalisti din Iasi 2010, 114:185-188.
27. Millanta F., Caneschi V., Ressel L., Citi S., Poli A. Expression of vascular endothelial growth factor in canine inflammatory and non-inflammatory mammary carcinoma. Journal of Comparative Pathology 2010, 142:36-42.
28. Muir P., Schaefer S.L., Manley P.A., Svaren J.P., Oldenhoff W.E., et al. Expression of immune response genes in the stifle joint of dogs with oligoarthritis and degenerative cranial cruciate ligament rupture. Veterinary Immunology and Immunopathology 2007, 119:214-221.
29. Nagel H., Laskawi R., Wahlers A., Hemmerlein B. Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1, -2, and -3 in benign and malignant tumours of the salivary gland. Histopathology 2004, 44:222-231.
30. Nakaichi M., Yunuki T., Okuda M., Une S., Taura Y. Activity of matrix metalloproteinase-2 (MMP-2) in canine oronasal tumors. Research in Veterinary Science 2007, 82:271-279.
31. Onisto M., Riccio M.P., Scannapieco P., Caenazzo C., Griggio L., et al. Gelatinase A/TIMP-2 imbalance in lymph-node-positive breast carcinomas, as measured by RT-PCR. International Journal of Cancer 1995, 63:621-626.
32. Papparella S., Restucci B., Paciello O., Maiolino P. Expression of matrix metalloprotease-2 (MMP-2) and the activator membrane type 1 (MT1-MMP) in canine mammary carcinomas. Journal of Comparative Pathology 2002, 126:271-276.
33. Patnaik A.K., Ehler W.Y., MacEwen E.G. Canine cutaneous mast cell tumors: morphologic grading and survival time in 83 dogs. Veterinary Pathology 1984, 21:469-474.
34. Patruno R., Arpaia N., Gadaleta C.D., Passantino L., Zizzo N., et al. VEGF concentration from plasma-activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model. Journal of Cellular and Molecular Medicine 2009, 13:555-561.
35. Preziosi R., Sarli G., Paltrinieri M. Prognostic value of intratumoral vessel density in cutaneous mast cell tumor of the dog. Journal of Comparative Pathology 2004, 130:143-151.
36. Qiu C.W., Lin D.G., Wang J.Q., Li C.Y., Deng G.Z. Expression and significance of PTEN and VEGF in canine mammary gland tumours. Veterinary Research Communications 2008, 32:463-472.
37. Ranieri G., Labriola A., Achille G., Florio G., Zito A.F., et al. Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma. International Journal of Oncology 2002, 21:1317-1323.
38. Ranieri G., Passantino L., Patruno R., Passantino G., Jirillo F., et al. The dog mast cell tumour as a model to study the relationship between angiogenesis, mast cell density and tumour malignancy. Oncology Reports 2003, 10:1189-1193.
39. Rasmussen R. Quantification on the Light Cycler. Rapid Cycle Real-Time PCR: Methods and Applications 2001, 21-34. Springer, Heidelberg. S.C. Meuer, C. Wittwer, K. Nakagawara (Eds.).
40. Rebuzzi L., Willmann M., Sonneck K., Gleixner K.V., Florian S., et al. Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Veterinary Immunology and Immunopathology 2007, 115:320-333.
41. Restucci B., Maiolino P., Paciello O., Martano M., De Vico G., et al. Evaluation of angiogenesis in canine seminomas by quantitative immunohistochemistry. Journal of Comparative Pathology 2003, 128:252-259.
42. Restucci B., Papparella S., Maiolino P., De Vico G. Expression of vascular endothelial growth factor in canine mammary tumors. Veterinary Pathology 2002, 39:488-493.
43. Ribatti D., Vacca A., Nico B., Quondamatteo F., Ria R., et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. British Journal of Cancer 1999, 79:451-455.
44. Sakai H., Noda A., Shirai N., Iidaka T., Yanai T., et al. Proliferative activity of canine mast cell tumours evaluated by bromodeoxyuridine incorporation and Ki-67 expression. Journal of Comparative Pathology 2002, 127:233-238.
45. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370:61-65.
46. Scase T.J., Edwards D., Miller J., Henley W., Smith K., et al. Canine mast cell tumors: correlation of apoptosis and proliferation markers with prognosis. Journal of Veterinary Internal Medicine 2006, 20:151-158.
47. Schwartz M., Puff C., Stein V.M., Baumgärtner W., Tipold A. Marked MMP-2 transcriptional up-regulation in mononuclear leukocytes invading the subarachnoidal space in aseptic suppurative steroid-responsive meningitis-arteritis in dogs. Veterinary Immunology and Immunopathology 2010, 133:198-206.
48. Soulié P., Carrozzino F., Pepper M.S., Strongin A.Y., Poupon M.F., et al. Membrane-type-1 matrix metalloproteinase confers tumorigenicity on nonmalignant epithelial cells. Oncogene 2005, 24:1689-1697.
49. Stetler-Stevenson W.G. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. American Journal of Pathology 1996, 148:1345-1350.
50. Stetler-Stevenson W.G., Krutzsch H.C., Liotta L.A. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. Journal of Biological Chemistry 1989, 264:17374-17378.
51. Takagi S., Kato Y., Asano K., Ohsaki T., Bosnakovski D., et al. Matrix metalloproteinase inhibitor RECK expression in canine tumors. Journal of Veterinary Medical Sciences 2005, 67:761-767.
52. Takanami I., Takeuchi K., Naruke M. Mast cell density is associated with angiogenesis and poor prognosis in pulmonary adenocarcinoma. Cancer 2000, 88:2686-2692.
53. Thamm D.H., Vail D.M. Mast cell tumors. Small Animal Clinical Oncology 2007, 402-424. WB Saunders, Philadelphia. 4th Edit. S.J. Withrow, E.G. MacEwen (Eds.).
54. Tuna B., Yorukoglu K., Unlu M., Mungan M.U., Kirkali Z. Association of mast cells with microvessel density in renal cell carcinomas. European Urology 2006, 50:530-534.
55. Uchida N., Nagai K., Sakurada Y., Shirota K. Distribution of VEGF and flt-1 in the normal dog tissues. Journal of Veterinary Medical Sciences 2008, 70:1273-1276.
56. Webster J.D., Yuzbasiyan-Gurkan V., Miller R.A., Kaneene J.B., Kiupel M. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication. Veterinary Pathology 2007, 44:298-308.
57. Welle M.M., Rohrer Bley C., Howard J., Rüfenacht S. Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment. Veterinary Dermatology 2008, 19:321-339.
58. Will H., Atkinson S.J., Butler G.S., Smith B., Murphy G. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. Journal of Biological Chemistry 1996, 271:17119-17123.
59. Wolfesberger B., Guija de Arespacohaga A., Willmann M., Gerner W., Miller I., et al. Expression of vascular endothelial growth factor and its receptors in canine lymphoma. Journal of Comparative Pathology 2007, 137:30-40.
60. Wolfesberger B., Tonar Z., Witter K., Guija de Arespacohaga A., Skalicky M., et al. Microvessel density in normal lymph nodes and lymphomas of dogs and their correlation with vascular endothelial growth factor expression. Research in Veterinary Science 2008, 85:56-61.